Genome-wide CRISPR/Cas9 screening for drug resistance in tumors

被引：12

作者：

Zhang, Zhongyan ^{[1
,2
]}

Wang, Hailiang ^{[1
,2
,3
]}

Yan, Qian ^{[1
,4
]}

Cui, Jinwei ^{[1
,4
]}

Chen, Yubin ^{[1
,4
]}

Ruan, Shiye ^{[1
,2
]}

Yang, Jiayu ^{[1
,2
]}

Wu, Zelong ^{[1
,2
]}

Han, Mingqian ^{[1
,2
]}

Huang, Shanzhou ^{[1
]}

Zhou, Qi ^{[5
,6
]}

Zhang, Chuanzhao ^{[1
]}

Hou, Baohua ^{[1
,2
]}

机构：

[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Gen Surg, Guangzhou, Peoples R China

[2] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China

[3] Qingdao Univ, Weihai Cent Hosp, Dept Hepatobiliary Surg, Weihai, Peoples R China

[4] South China Univ Technol, Sch Med, Guangzhou, Peoples R China

[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Liver Surg, Guangzhou, Peoples R China

[6] Sun Yat Sen Univ, Hui Ya Hosp, Affiliated Hosp 1, Dept Gen Surg, Huizhou, Guangdong, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2023年 / 14卷

关键词：

drug resistance; tumors; genome-wide CRISPR/Cas9 screening; MAPK pathway inhibitors; PARP inhibitors; TRANSCRIPTIONAL ACTIVATION; SORAFENIB RESISTANCE; CRISPR-CAS9; MECHANISMS; SENSITIVITY; EXPRESSION; VULNERABILITIES;

D O I：

10.3389/fphar.2023.1284610

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated nuclease 9 (Cas9) screening is a simple screening method for locating loci under specific conditions, and it has been utilized in tumor drug resistance research for finding potential drug resistance-associated genes. This screening strategy has significant implications for further treatment of malignancies with acquired drug resistance. In recent years, studies involving genome-wide CRISPR/Cas9 screening have gradually increased. Here we review the recent application of genome-wide CRISPR/Cas9 screening for drug resistance, involving mitogen-activated protein kinase (MAPK) pathway inhibitors, poly (ADP-ribose) polymerase inhibitors (PARPi), alkylating agents, mitotic inhibitors, antimetabolites, immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase inhibitors (CDKI). We summarize drug resistance pathways such as the KEAP1/Nrf2 pathway MAPK pathway, and NF-kappa B pathway. Also, we analyze the limitations and conditions for the application of genome-wide CRISPR/Cas9 screening techniques.

引用

页数：15

共 102 条

[1] Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer [J].

Abu Samaan, Tala M. ;

Samec, Marek ;

Liskova, Alena ;

Kubatka, Peter ;

Busselberg, Dietrich .

BIOMOLECULES, 2019, 9 (12)

[2] Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells [J].

Bakke, Jesse ;

Wright, William C. ;

Zamora, Anthony E. ;

Oladimeji, Peter ;

Crawford, Jeremy Chase ;

Brewer, Christopher T. ;

Autry, Robert J. ;

Evans, William E. ;

Thomas, Paul G. ;

Chen, Taosheng .

BMC CANCER, 2019, 19 (1)

[3] The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells [J].

Barazas, Marco ;

Annunziato, Stefano ;

Pettitt, Stephen J. ;

de Krijger, Inge ;

Ghezraoui, Hind ;

Roobol, Stefan J. ;

Lutz, Catrin ;

Frankum, Jessica ;

Song, Fei Fei ;

Brough, Rachel ;

Evers, Bastiaan ;

Gogola, Ewa ;

Bhin, Jinhyuk ;

van de Ven, Marieke ;

van Gent, Dik C. ;

Jacobs, Jacqueline J. L. ;

Chapman, Ross ;

Lord, Christopher J. ;

Jonkers, Jos ;

Rottenberg, Sven .

CELL REPORTS, 2018, 23 (07) :2107-2118

[4] miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways [J].

Bi, Guoshu ;

Liang, Jiaqi ;

Zhao, Mengnan ;

Zhang, Huan ;

Jin, Xing ;

Lu, Tao ;

Zheng, Yuansheng ;

Bian, Yunyi ;

Chen, Zhencong ;

Huang, Yiwei ;

Besskaya, Valeria ;

Zhan, Cheng ;

Wang, Qun ;

Tan, Lijie .

MOLECULAR THERAPY NUCLEIC ACIDS, 2022, 28 :366-386

[5] CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity [J].

Burr, Marian L. ;

Sparbier, Christina E. ;

Chan, Yih-Chih ;

Williamson, James C. ;

Woods, Katherine ;

Beavis, Paul A. ;

Lam, Enid Y. N. ;

Henderson, Melissa A. ;

Bell, Charles C. ;

Stolzenburg, Sabine ;

Gilan, Omer ;

Bloor, Stuart ;

Noori, Tahereh ;

Morgens, David W. ;

Bassik, Michael C. ;

Neeson, Paul J. ;

Behren, Andreas ;

Darcy, Phillip K. ;

Dawson, Sarah-Jane ;

Voskoboinik, Ilia ;

Trapani, Joseph A. ;

Cebon, Jonathan ;

Lehner, Paul J. ;

Dawson, Mark A. .

NATURE, 2017, 549 (7670) :101-105

[6] Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma [J].

Cai, Jun ;

Chen, Jianfei ;

Wu, Tiantian ;

Cheng, Zhilei ;

Tian, Yuanhu ;

Pu, Changsheng ;

Shi, Wenzai ;

Suo, Xiaopeng ;

Wu, Xianjia ;

Zhang, Keming .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 526 (04) :1170-1176

[7] Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases [J].

Cargnello, Marie ;

Roux, Philippe P. .

MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2011, 75 (01) :50-83

[8] CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway [J].

Chen, Jiang ;

Jiang, Shi ;

Shao, Huijiang ;

Li, Bixia ;

Ji, Tong ;

Staiculescu, Daniel ;

He, Jiayan ;

Zhao, Jie ;

Cai, Liuxin ;

Liang, Xiao ;

Xu, Junjie ;

Cai, Xiujun .

SCIENCE CHINA-LIFE SCIENCES, 2022, 65 (10) :1998-2016

[9] Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models [J].

Daggubati, Vikas ;

Hochstelter, Jordan ;

Bommireddy, Anirudh ;

Choudhury, Abrar ;

Krup, Alexis Leigh ;

Kaur, Pervinder ;

Tong, Pakteema ;

Li, Amy ;

Xu, Libin ;

Reiter, Jeremy F. ;

Raleigh, David R. .

JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (06)

[10]

Datlinger P, 2017, NAT METHODS, V14, P297, DOI [10.1038/NMETH.4177, 10.1038/nmeth.4177]

← 1 2 3 4 5 6 7 8 9 10 →